Alloy Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alloy Therapeutics, Inc.
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
In the United States, where Black inequity has become a focus of diversity efforts, biopharma companies are working hard to recruit and retain individuals from these communities. In fact, the search for such employees and leaders has become so competitive that competition for diverse talent within the industry is now "fierce," as one executive told In Vivo.
Private Company Edition: Third quarter venture capital funding for biopharmaceutical firms fell from Q2, but activity remains near all-time highs year-to-date. Several companies announced VC financings in early October, including Ascidian, which launched with $50m in series A financing.
The Amsterdam-based group will use proceeds from the financing to progress its pipeline of genetic modifiers in cancer and rare diseases.
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.